Skip to main content
Equibles
BDSX logo

BDSX · Biodesix Inc · Earnings Call Transcripts & Audio

Track BDSX — free

Use BDSX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BDSX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$26.04 -1.04 (-3.84%) At close · Sep 10
Rebalance outlook locked
Market Cap
$283.09M
Shares
10.55M

Biodesix Inc Earnings Call Transcripts

Quarterly earnings calls for Biodesix Inc (BDSX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲70.1% $11.11M −$13.70M '22 Q3 22-10-11 ▲33% $9.61M −$20.34M '22 Q4 23-03-06 ▲38.3% $9.06M −$18.70M '23 Q1 23-05-11 ▲8.4% $11.87M −$13.36M '23 Q2 23-08-07 ▲21.5% $13.49M −$10.95M '23 Q3 23-11-07 ▲52.7% $14.67M −$9.14M '23 Q4 24-03-01 ▲63.6% $14.82M −$13.61M '24 Q1 24-05-08 ▲51% $17.93M −$10.81M '24 Q2 24-08-07 ▲34.5% $18.15M −$10.26M '24 Q3 24-11-01 ▲39.3% $20.43M −$8.25M '24 Q4 25-01-10 ▲21.2% $17.96M −$11.10M '25 Q1 25-05-13 ▲11.7% $20.02M −$11.47M '25 Q2 25-08-07 ▲19.9% $21.77M −$8.72M '25 Q3 25-11-03 ▲40.8% $28.75M −$3.98M '25 Q4 26-02-26 ▲42.3% $25.55M −$7.79M '26 Q1 26-05-04 LATEST ▲34.2% $26.86M −$7.27M '26 Q2 26-08-05
Conference
Investor event
2026-08-12
Biodesix Inc (BDSX) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Biodesix Inc (BDSX) Q2 2026 Earnings Call Transcript
Confident tone Diagnostic test volume and revenue growth Clinical evidence and publications Primary care market expansion
Revenue
$26.86M
▲ 34.2% YoY
Diluted EPS
$-0.71
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Biodesix Inc (BDSX) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-04
Biodesix Inc (BDSX) Q1 2026 Earnings Call Transcript
Confident tone Lung Diagnostic Testing Growth Profitability and Operating Leverage Development Services / Biopharma
Revenue
$25.55M
▲ 42.3% YoY
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Biodesix Inc (BDSX) Q4 2025 Earnings Call Transcript
Confident tone Lung Diagnostics Growth HEDIS / Lung Cancer Screening Guidelines Profitability Milestones
Revenue
$28.75M*
▲ 40.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Biodesix Inc (BDSX) Q3 2025 Earnings Call Transcript
Confident tone Lung diagnostics / Nodify testing Sales force productivity and expansion Revenue and margin growth
Revenue
$21.77M
▲ 19.9% YoY
Diluted EPS
$-1.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Biodesix Inc (BDSX) Q2 2025 Earnings Call Transcript
Positive tone Lung nodule diagnostic commercial expansion Primary care sales strategy Development Services / biopharma
Revenue
$20.02M
▲ 11.7% YoY
Diluted EPS
$-1.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Biodesix Inc (BDSX) Q1 2025 Earnings Call Transcript
Positive tone Primary Care Commercial Expansion Sales Team Reconfiguration Lung Diagnostics Growth (Nodify)
Revenue
$17.96M
▲ 21.2% YoY
Diluted EPS
$-1.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Biodesix Inc (BDSX) Q4 2024 Earnings Call Transcript
Positive tone Lung disease market opportunity Clinical studies and evidence generation Diagnostic development services / biopharma
Revenue
$20.43M*
▲ 39.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-01
Biodesix Inc (BDSX) Q3 2024 Earnings Call Transcript
Positive tone Sales team expansion and productivity Lung diagnostic test growth and adoption Hurricane impact on Q3 operations
Revenue
$18.15M
▲ 34.5% YoY
Diluted EPS
$-1.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Biodesix Inc (BDSX) Q2 2024 Earnings Call Transcript
Confident tone Lung diagnostic test growth and volume Revenue guidance raise and financial performance Operational efficiency and facilities
Revenue
$17.93M
▲ 51% YoY
Diluted EPS
$-1.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Biodesix Inc (BDSX) Q1 2024 Earnings Call Transcript
Confident tone Lung Diagnostic test volume growth Gross margin expansion Path to profitability / adjusted EBITDA
Revenue
$14.82M
▲ 63.6% YoY
Diluted EPS
$-2.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-01
Biodesix Inc (BDSX) Q4 2023 Earnings Call Transcript
Confident tone Lung diagnostic test volume growth Biopharmaceutical services Sales force expansion
Revenue
$14.67M*
▲ 52.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Biodesix Inc (BDSX) Q3 2023 Earnings Call Transcript
Revenue
$13.49M
▲ 21.5% YoY
Diluted EPS
$-2.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Biodesix Inc (BDSX) Q2 2023 Earnings Call Transcript
Revenue
$11.87M
▲ 8.4% YoY
Diluted EPS
$-3.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Biodesix Inc (BDSX) Q1 2023 Earnings Call Transcript
Revenue
$9.06M
▲ 38.3% YoY
Diluted EPS
$-4.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Biodesix Inc (BDSX) Q4 2022 Earnings Call Transcript
Revenue
$9.61M*
▲ 33% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-11
Biodesix Inc (BDSX) Q3 2022 Earnings Call Transcript
Revenue
$11.11M
▲ 70.1% YoY
Diluted EPS
$-6.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Biodesix Inc (BDSX) Q2 2022 Earnings Call Transcript
Revenue
$10.95M
▼ 7.9% YoY
Diluted EPS
$-8.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Biodesix Inc (BDSX) Q1 2022 Earnings Call Transcript
Revenue
$6.55M
▼ 77.3% YoY
Diluted EPS
$-10.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-14
Biodesix Inc (BDSX) Q4 2021 Earnings Call Transcript
Revenue
$7.22M*
▼ 73.3% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Biodesix Inc (BDSX) Q3 2021 Earnings Call Transcript
Revenue
$6.53M
▼ 29% YoY
Diluted EPS
$-8.20
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Biodesix Inc (BDSX) Q2 2021 Earnings Call Transcript
Revenue
$11.88M
▲ 180.4% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Biodesix Inc (BDSX) Q1 2021 Earnings Call Transcript
Revenue
$28.87M
▲ 466.4% YoY
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts CIK 1439725 CUSIP 09075X207 13F (30d) 26 filings 26 filers Visit website Investor relations